{"id":71446,"date":"2026-05-20T11:50:00","date_gmt":"2026-05-20T11:50:00","guid":{"rendered":"https:\/\/medsbase.com\/aod-9604\/"},"modified":"2026-05-21T07:14:08","modified_gmt":"2026-05-21T07:14:08","slug":"aod-9604","status":"publish","type":"product","link":"https:\/\/medsbase.com\/cs\/product\/aod-9604\/","title":{"rendered":"AOD-9604 (l\u00e9k proti obezit\u011b 9604 \/ Tyr-hGH 177-191)"},"content":{"rendered":"

<\/p>\n

\n

Rychl\u00e1 odpov\u011b\u010f \u2014 Co je AOD-9604?<\/h3>\n

AOD-9604<\/strong> (\u201cAnti-Obesity Drug 9604\u201d, CAS 221231-10-3) je syntetick\u00fd 16-aminokyselinov\u00fd peptid vyvinut\u00fd spole\u010dnost\u00ed Metabolic Pharmaceuticals Ltd<\/strong> (Austr\u00e1lie) koncem 90. let jako stabilizovan\u00fd analog C-termin\u00e1ln\u00edho lipolytick\u00e9ho fragmentu lidsk\u00e9ho r\u016fstov\u00e9ho hormonu. Sekvence Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (16 aa, s N-termin\u00e1ln\u00ed tyrosinovou extenz\u00ed stabilizuj\u00edc\u00ed mate\u0159sk\u00fd fragment hGH 177\u2013191 a s intramolekul\u00e1rn\u00edm disulfidov\u00fdm m\u016fstkem Cys7\u2013Cys14). Molekul\u00e1rn\u00ed vzorec C78<\/sub>H123<\/sub>N23<\/sub>O23<\/sub>S2<\/sub>, MW 1815,1 Da. V publikovan\u00fdch in-vitro a preklinick\u00fdch studi\u00edch si AOD-9604 zachov\u00e1v\u00e1 lipolytickou a anti-lipogenn\u00ed aktivitu<\/strong> mate\u0159sk\u00e9 molekuly hGH, ale nev\u00e1\u017ee se ne<\/em> na receptor GH \u2014 neindukuje tedy IGF-1, neaktivuje signalizaci r\u016fstov\u00e9 osy JAK2\/STAT5 a nevykazuje r\u016fstov\u00e9 \u00fa\u010dinky pln\u00e9 d\u00e9lky HGH. Ne\u00fasp\u011b\u0161n\u00e9 klinick\u00e9 hodnocen\u00ed f\u00e1ze IIb pro obezitu (2007); nyn\u00ed pou\u017e\u00edv\u00e1n jako v\u00fdzkumn\u00fd peptid. Pouze pro laboratorn\u00ed v\u00fdzkum.<\/em><\/p>\n<\/div>\n

Co z\u00edsk\u00e1te s MedsBase:<\/strong> Lyofilizovan\u00fd pr\u00e1\u0161ek \u226599% HPLC-verifikovan\u00fd \u00b7 COA dostupn\u00fd na vy\u017e\u00e1d\u00e1n\u00ed \u00b7 Diskr\u00e9tn\u00ed teplotn\u011b stabiln\u00ed balen\u00ed \u00b7 Celosv\u011btov\u00e1 dod\u00e1vka v\u00fdzkumn\u00fdch materi\u00e1l\u016f \u00b7 1,400+ ov\u011b\u0159en\u00fdch recenz\u00ed z\u00e1kazn\u00edk\u016f<\/a><\/div>\n

\ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Specifikace<\/th>\nDetail<\/th>\n<\/tr>\n<\/thead>\n
T\u0159\u00edda slou\u010denin<\/strong><\/td>\nSyntetick\u00fd 16-aminokyselinov\u00fd peptid; stabilizovan\u00fd analog C-termin\u00e1ln\u00edho fragmentu hGH; lipolytick\u00fd\/anti-lipogenn\u00ed v\u00fdzkumn\u00fd peptid (odd\u011blen\u00fd od vazby na GH receptor)<\/td>\n<\/tr>\n
Chemick\u00fd n\u00e1zev<\/strong><\/td>\nAOD-9604 (\u201cAnti-Obesity Drug 9604\u201d; synonyma: Tyr-hGH 177-191; H-Tyr-(177-191 hGH fragment)-OH)<\/td>\n<\/tr>\n
CAS \u010d\u00edslo<\/strong><\/td>\n221231-10-3 (k\u00e1nonick\u00e9 reference Sigma-Aldrich, MedKoo, ChemicalBook)<\/td>\n<\/tr>\n
item2<\/strong><\/td>\nC78<\/sub>H123<\/sub>N23<\/sub>O23<\/sub>S2<\/sub><\/td>\n<\/tr>\n
item7<\/strong><\/td>\n1815,1 g\/mol<\/td>\n<\/tr>\n
item9<\/strong><\/td>\nTyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (jednop\u00edsmenn\u00fd k\u00f3d: YLRIVQCRSVEGSCGF; 16 aminokyselin). Intramolekul\u00e1rn\u00ed disulfidov\u00fd m\u016fstek Cys7\u2013Cys14 vytv\u00e1\u0159\u00ed cyklickou strukturu napodobuj\u00edc\u00ed disulfidovou geometrii mate\u0159sk\u00e9 oblasti hGH 182\u2013189. N-termin\u00e1ln\u00ed tyrosin je syntetick\u00fd dodatek (nep\u0159\u00edtomn\u00fd v nativn\u00edm hGH 177\u2013191), kter\u00fd stabilizuje fragment proti proteolytick\u00e9 degradaci na aminokonci.<\/td>\n<\/tr>\n
Mechanismus \u00fa\u010dinku<\/strong><\/td>\nMechanisticky odd\u011blen\u00e1 lipol\u00fdza<\/strong>. AOD-9604 se NEv\u00e1\u017ee na receptor GH (GHR) \u2014 vazebn\u00e1 plocha GHR u nativn\u00edho hGH le\u017e\u00ed v N-termin\u00e1ln\u00ed \u010d\u00e1sti (oblast zbytk\u016f 1\u2013120), kter\u00e1 chyb\u00ed ve fragmentu 176\u2013191. P\u0159edpokl\u00e1d\u00e1 se, \u017ee lipolytick\u00e1\/anti-lipogenn\u00ed aktivita je zprost\u0159edkov\u00e1na signalizac\u00ed p\u0159es \u03b23-adrenergn\u00ed receptor a p\u0159\u00edmou aktivac\u00ed hormon-senzitivn\u00ed lip\u00e1zy (HSL) adipocyt\u016f p\u0159es cAMP-PKA. Mechanismus nen\u00ed v publikovan\u00e9 literatu\u0159e pln\u011b charakterizov\u00e1n \u2014 neexistuje jedin\u00fd potvrzen\u00fd receptor pro C-termin\u00e1ln\u00ed lipolytick\u00fd fragment.<\/td>\n<\/tr>\n
Plazmatick\u00fd polo\u010das<\/strong><\/td>\n~4 minuty (velmi kr\u00e1tk\u00e9 \u2014 zp\u016fsoben\u00e9 proteolytick\u00fdm od\u0161t\u011bpen\u00edm N-konce i p\u0159es stabilizuj\u00edc\u00ed Tyr). Tato kr\u00e1tk\u00e1 polo\u010dasov\u00e1 doba je jednou z hlavn\u00edch hypot\u00e9z, pro\u010d klinick\u00e9 hodnocen\u00ed f\u00e1ze IIb pro obezitu (2007) nedos\u00e1hlo redukce hmotnosti \u2014 fragment je degradov\u00e1n d\u0159\u00edve, ne\u017e m\u016f\u017ee doj\u00edt k dostate\u010dn\u00e9 expozici receptoru v c\u00edlov\u00e9 tk\u00e1ni.<\/td>\n<\/tr>\n
item11<\/strong><\/td>\nLyofilizovan\u00fd b\u00edl\u00fd a\u017e sv\u011btle \u017elut\u00fd amorfn\u00ed pr\u00e1\u0161ek; jednor\u00e1zov\u00e9 v\u00fdzkumn\u00e9 vialky<\/td>\n<\/tr>\n
item13<\/strong><\/td>\n\u226599% (ov\u011b\u0159eno HPLC); MALDI-TOF hmotnostn\u00ed spektrometrie potvrzuje 1815,1 Da. Certifik\u00e1t anal\u00fdzy na vy\u017e\u00e1d\u00e1n\u00ed.<\/td>\n<\/tr>\n
Rozpustnost<\/strong><\/td>\nRozpustn\u00fd v bakteriostatick\u00e9 vod\u011b, steriln\u00ed vod\u011b, PBS a 0,1% kyselin\u011b octov\u00e9 p\u0159i \u22655 mg\/ml; snadno rozpustn\u00fd v DMSO p\u0159i \u226550 mg\/ml pro p\u0159\u00edpravu in-vitro z\u00e1sobn\u00edho roztoku. Disulfidov\u00fd m\u016fstek Cys7\u2013Cys14 omezuje geometrii peptidu, ale nebr\u00e1n\u00ed jeho rozpustnosti ve vod\u011b.<\/td>\n<\/tr>\n
Skladov\u00e1n\u00ed<\/strong><\/td>\nLyofilizovan\u00fd: 2\u20138 \u00b0C neotev\u0159en\u00fd pro kr\u00e1tkodob\u00e9 pracovn\u00ed z\u00e1soby; \u221220 \u00b0C pro dlouhodob\u00e9 skladov\u00e1n\u00ed (stabiln\u00ed \u226536 m\u011bs\u00edc\u016f p\u0159i \u221220 \u00b0C; \u226518 m\u011bs\u00edc\u016f p\u0159i 2\u20138 \u00b0C). Rekonstituovan\u00fd vodn\u00fd roztok: 2\u20138 \u00b0C, pou\u017eijte do ~30 dn\u016f. Chra\u0148te p\u0159ed sv\u011btlem. Vyhn\u011bte se opakovan\u00fdm cykl\u016fm zmrazen\u00ed\u2013rozmrazen\u00ed rekonstituovan\u00e9ho roztoku \u2014 disulfidov\u00fd m\u016fstek je stabiln\u00ed p\u0159i jednom cyklu zmrazen\u00ed-rozmrazen\u00ed, ale kumulativn\u00ed cykly mohou v\u00e9st k p\u0159eskupen\u00ed voln\u00fdch thiol\u016f a \u010d\u00e1ste\u010dn\u00e9 agregaci.<\/td>\n<\/tr>\n
Pouze pro v\u00fdzkum<\/strong><\/td>\nPouze pro laboratorn\u00ed v\u00fdzkum. Nen\u00ed ur\u010deno pro diagnostick\u00e9 nebo terapeutick\u00e9 pou\u017eit\u00ed u lid\u00ed nebo zv\u00ed\u0159at. AOD-9604 nen\u00ed na sou\u010dasn\u00e9m seznamu zak\u00e1zan\u00fdch l\u00e1tek WADA pod sv\u00fdm specifick\u00fdm n\u00e1zvem, ale v\u00fdzkumn\u00edci by m\u011bli b\u00fdt v\u011bdomi, \u017ee \u0161ir\u0161\u00ed t\u0159\u00edda S2 (peptidov\u00e9 hormony, r\u016fstov\u00e9 faktory, p\u0159\u00edbuzn\u00e9 l\u00e1tky a mimetika) zahrnuje fragmenty r\u016fstov\u00e9ho hormonu a p\u0159\u00edbuzn\u00e9 slou\u010deniny. AOD-9604 dos\u00e1hl f\u00e1ze IIb klinick\u00fdch studi\u00ed pro obezitu, ale nez\u00edskal regula\u010dn\u00ed schv\u00e1len\u00ed; australsk\u00fd TGA v jedn\u00e9 f\u00e1zi uvedl AOD-9604 jako povolenou slo\u017eku pro omezen\u00e9 pou\u017eit\u00ed ve v\u00fdzkumn\u00e9m kontextu, s n\u00e1sledn\u00fdmi regula\u010dn\u00edmi up\u0159esn\u011bn\u00edmi, kter\u00e1 se li\u0161\u00ed podle jurisdikce.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

<\/p>\n

Co je AOD-9604?<\/h2>\n

AOD-9604<\/strong> (\u201cAnti-Obesity Drug 9604\u201d; CAS 221231-10-3) je syntetick\u00fd 16-aminokyselinov\u00fd peptid vyvinut\u00fd Metabolic Pharmaceuticals Ltd<\/strong> na Monash University v Melbourne v Austr\u00e1lii koncem 90. let 20. stolet\u00ed. Jedn\u00e1 se o stabilizovan\u00fd analog C-termin\u00e1ln\u00edho lipolytick\u00e9ho fragmentu p\u0159irozen\u00e9ho lidsk\u00e9ho r\u016fstov\u00e9ho hormonu (zbytky 177\u2013191), ke kter\u00e9mu byla p\u0159id\u00e1na N-termin\u00e1ln\u00ed tyrosin, aby se zpomalila proteolytick\u00e1 degradace aminokonce. Sekvence Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (YLRIVQCRSVEGSCGF), s p\u0159irozen\u00fdm Cys182\u2013Cys189 intramolekul\u00e1rn\u00edm disulfidov\u00fdm m\u016fstkem mate\u0159sk\u00e9ho hGH zachovan\u00fdm jako Cys7\u2013Cys14 v r\u00e1mci \u010d\u00edslov\u00e1n\u00ed fragmentu. Molekulov\u00e1 hmotnost 1815,1 g\/mol, empirick\u00fd vzorec C78<\/sub>H123<\/sub>N23<\/sub>O23<\/sub>S2<\/sub>.<\/p>\n

Farmakologick\u00e1 logika za AOD-9604 je jedn\u00edm z nej\u010dist\u0161\u00edch p\u0159\u00edklad\u016f strukturn\u011b-funk\u010dn\u00ed anal\u00fdzy ve v\u00fdzkumu peptid\u016f HGH. P\u0159irozen\u00fd pln\u011b dlouh\u00fd lidsk\u00fd r\u016fstov\u00fd hormon (191 aminokyselin) m\u00e1 alespo\u0148 dv\u011b odli\u0161n\u00e9 biologick\u00e9 aktivity: r\u016fstov\u00e9 \/ anabolick\u00e9 \u00fa\u010dinky<\/strong> (zprost\u0159edkovan\u00e9 p\u0159es receptor GH, signalizaci JAK2\/STAT5 a n\u00e1slednou produkci IGF-1) a lipolytick\u00e9 \/ anti-lipogenn\u00ed \u00fa\u010dinky<\/strong> (zprost\u0159edkovan\u00e9 p\u0159es samostatn\u00fd, ne zcela charakterizovan\u00fd mechanismus, kter\u00fd nevy\u017eaduje zapojen\u00ed receptoru GH). Hypot\u00e9za skupiny Monash byla, \u017ee lipolytick\u00e1 aktivita je zak\u00f3dov\u00e1na v C-termin\u00e1ln\u00ed oblasti molekuly \u2014 a \u017ee syntetick\u00fd peptid zahrnuj\u00edc\u00ed pouze tuto oblast by mohl zachovat aktivitu mobilizuj\u00edc\u00ed tuky, zat\u00edmco by ztratil aktivitu zapojuj\u00edc\u00ed r\u016fstovou osu. To se uk\u00e1zalo jako spr\u00e1vn\u00e9 v publikovan\u00e9m in-vitro a pokusech na hlodavc\u00edch: fragment 176\u2013191 si zachov\u00e1v\u00e1 lipolytickou a anti-lipogenn\u00ed aktivitu v kultu\u0159e adipocyt\u016f a modelech my\u0161\u00ed s dietou indukovanou obezitou (DIO), ale nev\u00e1\u017ee se na GHR, neaktivuje JAK2\/STAT5 a neindukuje IGF-1.<\/p>\n

AOD-9604 pro\u0161el n\u011bkolika klinick\u00fdmi studiemi f\u00e1ze I a II na po\u010d\u00e1tku a\u017e v polovin\u011b 2000. let, vyvrcholen\u00edm byla 28t\u00fddenn\u00ed studie f\u00e1ze IIb obezity (~500 pacient\u016f) dokon\u010den\u00e1 v roce 2007 spole\u010dnost\u00ed Metabolic Pharmaceuticals. Studie nedos\u00e1hla sv\u00e9ho prim\u00e1rn\u00edho c\u00edle v podob\u011b \u00fabytku hmotnosti a v\u00fdvojov\u00fd program v oblasti farmakologie obezity byl ukon\u010den. AOD-9604 n\u00e1sledn\u011b vstoupil na trh s v\u00fdzkumn\u00fdmi peptidy a neregulovan\u00fdmi dopl\u0148ky, kde z\u016fst\u00e1v\u00e1 jedn\u00edm z nej\u010dast\u011bji citovan\u00fdch \u201cpeptid\u016f pro ztr\u00e1tu tuku\u201d v neklinick\u00e9 literatu\u0159e. Slou\u010denina si zachov\u00e1v\u00e1 v\u00fdzkumn\u00fd potenci\u00e1l jako kanonick\u00fd farmakologick\u00fd n\u00e1stroj pro studium lipol\u00fdzy odd\u011blen\u00e9 od GHR, biologii C-termin\u00e1ln\u00edho fragmentu hGH a strukturn\u011b-funk\u010dn\u00ed z\u00e1klad mnoha\u010detn\u00fdch aktivit HGH.<\/p>\n

Pozn\u00e1mka k n\u00e1zvoslov\u00ed: AOD-9604 a \u201cHGH Fragment 176-191<\/a>\u201d se na trhu dodavatel\u016f a v\u00fdzkumn\u00fdch peptid\u016f \u010dasto pou\u017e\u00edvaj\u00ed zam\u011bniteln\u011b. P\u0159\u00edsn\u011b vzato, AOD-9604 (CAS 221231-10-3) je analog vyvinut\u00fd spole\u010dnost\u00ed Metabolic Pharmaceuticals s N-termin\u00e1ln\u00ed Tyr stabilizac\u00ed. \u201cHGH Fragment 176-191\u201d (CAS 66004-57-7 podle n\u011bkter\u00fdch referenc\u00ed) je star\u0161\u00ed, nestabilizovan\u00fd fragment hGH 177\u2013191, z n\u011bho\u017e byl AOD-9604 odvozen. Oba sd\u00edlej\u00ed stejnou aminokyselinovou sekvenci YLRIVQCRSVEGSCGF v mnoha p\u0159\u00edpravc\u00edch od dodavatel\u016f \u2014 ale ozna\u010den\u00ed AOD-9604 konkr\u00e9tn\u011b identifikuje registrovanou v\u00fdzkumnou slou\u010deninu Metabolic Pharmaceuticals. V\u00fdzkumn\u00edci by m\u011bli konzultovat COA, aby potvrdili, kter\u00e9 form\u011b odpov\u00edd\u00e1 dan\u00e1 \u0161ar\u017ee od dodavatele.<\/p>\n

Mechanismus \u00fa\u010dinku \u2014 Lipol\u00fdza odd\u011blen\u00e1 od GHR<\/h2>\n

Mechanismus AOD-9604 pat\u0159\u00ed k nejdiskutovan\u011bj\u0161\u00edm ve v\u00fdzkumu peptid\u016f HGH:<\/p>\n